Pustular Psoriasis: Pus-Filled Blisters on Red Skin

Clinical Overview

Pustular psoriasis is a severe, often acute-onset variant of psoriasis characterized by 1-5 mm sterile pustules on an erythematous base, occurring on normal or already psoriatic skin. The condition differs significantly from plaque psoriasis in both clinical presentation and severity; pustular psoriasis is potentially life-threatening, particularly in the generalized form, due to extensive body surface area involvement, systemic inflammation, and potential complications including infection, dehydration, and fever. Two main forms exist: generalized pustular psoriasis (also termed acute pustular psoriasis or von Zumbusch psoriasis), representing a medical emergency with rapid onset of widespread pustulation, fever, and systemic toxicity; and localized pustular psoriasis (palmoplantar pustulosis and acanthosis pustulosa palmaris et plantaris), with pustulation limited to palms and soles. Pustular psoriasis may develop de novo or may evolve from plaque psoriasis following abrupt corticosteroid withdrawal, infections, or other triggers. The condition typically requires systemic immunosuppressive therapy or biologic agents for disease control.

Epidemiology

Pustular psoriasis is rare, affecting approximately 0.5-1.0% of psoriasis patients in developed nations, with generalized pustular psoriasis being the rarer form (0.1-0.3% of psoriasis patients) and localized pustular psoriasis (palmoplantar pustulosis) accounting for most pustular psoriasis cases. Peak incidence of generalized pustular psoriasis occurs in adults aged 30-50 years, though the condition can present at any age including infancy (benign familial pemphigosus, autosomal dominant condition distinct from classic pustular psoriasis). Female slight predominance is noted (female-to-male ratio approximately 1.1-1.3:1). Risk factors for generalized pustular psoriasis include: abrupt corticosteroid withdrawal (responsible for 20-30% of cases), infections (particularly infections of respiratory tract or other systemic infections triggering exacerbation), pregnancy (rarely triggers generalized pustular psoriasis in previously quiescent patients), certain medications (lithium, beta-blockers, NSAIDs), and genetic predisposition (positive family history of psoriasis in 30-40%). Localized pustular psoriasis (palmoplantar pustulosis) is more common, affecting 0.2-0.5% of population; female predominance is marked (female-to-male ratio 4:1), and age of onset is typically 30-50 years. Smoking is strongly associated with palmoplantar pustulosis; approximately 60-80% of patients with localized pustular psoriasis are smokers or former smokers.

Pathophysiology

The pathophysiology of pustular psoriasis involves T cell-mediated immune response with Th17 skewing and TNF-α pathway activation, similar to plaque psoriasis, but with exaggerated inflammatory response and prominent neutrophil infiltration. Neutrophils accumulate in epidermis following chemotactic signals from inflammatory mediators including IL-17 and IL-8. The accumulation of neutrophils combined with keratinocyte activation results in pustule formation. Histologically, pustular psoriasis demonstrates characteristic findings: microabscesses (collections of neutrophils within epidermis), neutrophilic infiltrate in superficial dermis, and variable degree of acanthosis and parakeratosis. In generalized pustular psoriasis, systemic inflammation is prominent with elevation of acute phase reactants (CRP, ESR), cytokines, and inflammatory mediators. Triggers for progression from plaque psoriasis to pustular forms include: abrupt corticosteroid withdrawal (induces rapid inflammatory rebound), infections (particularly streptococcal or other systemic infections activate inflammatory pathways), pregnancy (hormonal changes and immune tolerance alteration), and medications including lithium and beta-blockers (which may enhance inflammatory response or trigger psoriasis exacerbation). Localized pustular psoriasis (palmoplantar pustulosis) has distinct pathophysiology emphasizing dermal involvement with IL-17 and TNF-α pathway activation; the association with smoking suggests that cigarette smoke constituents may trigger or perpetuate disease through irritant and immune-modulating mechanisms.

Clinical Presentation

Generalized pustular psoriasis (von Zumbusch psoriasis) presents acutely with sudden onset of extensive erythema and 1-3 mm pustules covering large body surface areas. Affected patients appear systemically ill with high fever (38-40°C), malaise, fatigue, and sometimes rigors. Pruritus and/or burning sensations are severe. Associated symptoms include headache, joint pain, and gastrointestinal symptoms. The pustules are sterile (negative bacterial culture) but appearance is dramatic with extensive "lakes" of erythema studded with pustules. Mucous membrane involvement may occur. Secondary bacterial infection occurs in 10-20% of patients, manifesting as increased purulence, cellulitis, and potential systemic toxicity. Dehydration from extensive inflammation, fluid loss through damaged skin barrier, and poor oral intake is common. Constitutional symptoms are severe, and many patients require hospitalization for supportive care, monitoring, and systemic therapy. Without treatment, mortality has historically approached 10-20% though modern therapy has substantially reduced this.

Localized pustular psoriasis (palmoplantar pustulosis) presents with 1-5 mm sterile pustules limited to palms, soles, and lateral aspects of hands and feet. Lesions are typically asymptomatic to moderately symptomatic with variable pruritus. The condition is chronic and follows a relapsing-remitting course with gradual accumulation of lesions over time. Systemic symptoms are absent. Secondary bacterial infection is uncommon. Functional impairment may occur if extensive palm involvement interferes with grasping or fine motor function.

Diagnosis

Diagnosis of generalized pustular psoriasis is clinical, based on characteristic presentation of rapid onset extensive pustulation with systemic symptoms in an acutely ill patient. Dermoscopy or biopsy reveals microabscesses. Skin biopsy confirms diagnosis showing neutrophilic microabscesses within epidermis and neutrophilic infiltrate in dermis. Bacterial culture of pustular fluid is sterile, distinguishing from infectious pustules. Complete blood count typically shows leukocytosis. Inflammatory markers (CRP, ESR) are elevated. Comprehensive metabolic panel should assess electrolytes, renal function, and liver function before initiating systemic therapy. Bacterial culture should be obtained from any suspicious lesions or sites of cellulitis.

Diagnosis of localized pustular psoriasis (palmoplantar pustulosis) is clinical, based on chronic recurrent pustulation limited to palms and soles. Dermoscopy and biopsy reveal similar histology to generalized form but with localized distribution. Evaluation for systemic markers of inflammation is generally not necessary unless systemic symptoms present. Imaging to assess for underlying arthropathy may be considered if joint symptoms develop.

Treatment Algorithm

Generalized pustular psoriasis is a medical emergency requiring hospitalization and aggressive systemic therapy. First-line systemic immunosuppressive agents include: acitretin (retinoid) at 0.5-1.0 mg/kg/day, cyclosporine 5 mg/kg/day, or biologic agents including TNF-α inhibitors. Acitretin produces response in 70-90% of patients within 2-4 weeks; it is FDA-approved specifically for pustular psoriasis. Cyclosporine at higher doses (5 mg/kg/day compared to 2.5-3.75 mg/kg/day for plaque psoriasis) produces rapid response (days to weeks). Biologic agents including TNF-α inhibitors (etanercept 50 mg twice weekly, infliximab 5 mg/kg IV, adalimumab 40 mg weekly) demonstrate excellent efficacy. IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (risankizumab) are increasingly recognized as effective alternatives. Systemic corticosteroids should be avoided unless necessary for bridging acute inflammation while awaiting response to other agents; prolonged corticosteroid use followed by withdrawal may trigger pustular transformation or worsen disease.

Supportive care is critical: maintain fluid and electrolyte balance through IV hydration if necessary, control fever with acetaminophen (avoid NSAIDs which may worsen psoriasis), monitor for secondary infections, provide comfort measures including cooling blankets, and ensure proper nutrition.

Localized pustular psoriasis treatment focuses on preventing secondary infection and controlling symptoms. Topical antimicrobials including benzoyl peroxide 5% or topical retinoids (tretinoin 0.025%) applied to palms and soles show modest efficacy. Intralesional corticosteroid injection may be beneficial for limited lesions. Systemic therapy is considered for extensive disease or significant functional impairment: acitretin 0.5-1.0 mg/kg/day, cyclosporine, or biologic agents are effective. Smoking cessation is critical, as smoking is strongly associated with disease persistence and severity.

Prognosis

The prognosis of generalized pustular psoriasis is serious; mortality was historically 10-20% in untreated patients but has substantially improved with modern systemic therapy to <1-2% with appropriate treatment. Approximately 80-90% of patients achieve significant response to systemic immunosuppressive therapy or biologic agents. Long-term prognosis depends on identification and elimination of triggering factors (avoiding corticosteroid withdrawal, treating concurrent infections) and maintaining effective systemic therapy. Localized pustular psoriasis has better prognosis; approximately 50-60% of patients achieve improvement with topical therapy and smoking cessation. However, 40-50% require ongoing systemic therapy for disease control.

When to See a Dermatologist

Generalized pustular psoriasis requires immediate emergency medical evaluation and hospitalization. Urgent dermatology consultation should be obtained concurrently. For localized pustular psoriasis, initial dermatologic evaluation is appropriate to confirm diagnosis and initiate therapy. Ongoing specialist care is necessary for both forms given the need for systemic therapy monitoring and potential for significant complications.

Frequently Asked Questions

Q: Are the pustules in pustular psoriasis infected? A: No, the pustules in pustular psoriasis are sterile—they do not contain bacteria. The pustules result from accumulation of white blood cells (neutrophils) in response to inflammation, not from bacterial infection. However, secondary bacterial infection can occur if pustules are traumatized or scratched.

Q: Why did my corticosteroid cream cause pustular psoriasis? A: Abrupt withdrawal of topical corticosteroids can trigger pustular transformation in psoriasis patients. This phenomenon is termed "pustular transformation" or "rebound pustular psoriasis." For this reason, corticosteroid discontinuation should be gradual, and alternative systemic therapy should be considered for patients at risk.

Q: Is pustular psoriasis life-threatening? A: Generalized pustular psoriasis can be life-threatening if untreated, with historical mortality of 10-20%. However, modern systemic therapy has substantially improved outcomes; mortality is now <1-2% with appropriate treatment. Prompt recognition and aggressive therapy are critical.

Q: Can pustular psoriasis turn into regular psoriasis? A: Pustular psoriasis can evolve from plaque psoriasis and conversely can improve to plaque psoriasis or clear entirely with appropriate treatment. The course is variable and depends on underlying triggers and response to therapy.

References